Oncoinvent reports favourable safety data for Radspherin in ovarian cancer trial
Oncoinvent has reported no treatment-related serious adverse events in the first randomised safety analysis of its Phase 2 Radspherin trial in ovarian cancer.
Oncoinvent has reported favourable interim safety data from a randomised Phase 2 trial of its radiopharmaceutical Radspherin in patients with advanced ovarian cancer, with no serious adverse events considered related to treatment.
The Norwegian biotech said the first randomised, controlled safety analysis showed that Radspherin was generally well tolerated when administered after surgery, alongside standard care, in patients with peritoneal metastases from ovarian cancer.
The trial, RAD-18-003 (NCT06504147), had randomised 74 patients as of 30 October 2026, in a 2:1 allocation between Radspherin and a control group. The safety analysis included 56 patients with primary ovarian cancer who had undergone complete surgical resection following neoadjuvant chemotherapy.
Of these, 40 received a single 7 MBq intraperitoneal dose of Radspherin after surgery in addition to standard care, while 16 received standard care alone.
There were no deaths, no adverse events leading to treatment discontinuation and no serious adverse events assessed as related to Radspherin.
Mild and moderate events reported
The proportion of patients experiencing treatment-emergent adverse events was similar in both groups. These events are those reported after treatment begins, regardless of whether they are caused by the investigational drug.
Ten events in five patients receiving Radspherin, representing 12.5% of the treatment group, were considered possibly related to the radiopharmaceutical. All were Grade 1 or 2, indicating mild or moderate severity.
The events included vomiting, nausea, abdominal pain, constipation, headache, dizziness, fatigue, anaemia and decreased lymphocyte count.
Most treatment-emergent adverse events in the Radspherin group were considered unrelated to the drug and consistent with the underlying disease and expected recovery following major abdominal surgery.
Professor Ignace Vergote, gynaecologic oncologist and professor emeritus at the Catholic University Leuven, said: “Women in this trial have just been through neoadjuvant chemotherapy and major abdominal surgery, so any treatment added afterwards must be well tolerated. It is encouraging to now see this in randomized data. The adverse events observed in both arms of the trial are what we would expect in patients recovering from this type of surgery, which is reassuring for patients and their physicians.”
The trial’s Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November and recommended that the study continue without modification.
Efficacy results expected in April 2027
The interim findings are consistent with safety observations from earlier Radspherin studies, according to Oncoinvent. These include the safety run-in cohort of the current trial, a Phase 1 study in recurrent ovarian cancer involving 21 patients, and a Phase 1/2a study in colorectal cancer involving 47 patients.
The company said no dose-limiting toxicity had been observed at the recommended 7 MBq dose in the earlier studies.
Radspherin is an investigational, receptor-independent alpha radiopharmaceutical being developed to target cancer cells in the abdominal cavity following surgery. The treatment is administered directly into the peritoneal cavity, with the aim of addressing residual disease after surgical removal of visible tumours.
Dr Zuzana Jirakova Trnkova, chief medical officer of Oncoinvent, said: “These first randomized data are an important milestone for Oncoinvent and for the Radspherin program. The safety profile is in line with what we have reported in previous studies, which strengthens our confidence as we move towards the efficacy readout in the spring and readiness for Phase 3. We thank the patients, investigators and site teams who made this possible.”
Recruitment is expected to finish in the first half of 2027. Oncoinvent plans to report interim efficacy data in April 2027, by which time close to all randomised patients are expected to be included. Approximately 40 patients will have at least nine months of follow-up.
The efficacy results will be important in determining whether the encouraging safety findings translate into a clinical benefit for patients with advanced ovarian cancer.




